Investors Still Aren't Entirely Convinced By Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Despite 37% Price Jump
Investors Still Aren't Entirely Convinced By Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Despite 37% Price Jump
Cytosorbents Corporation (NASDAQ:CTSO) shareholders are no doubt pleased to see that the share price has bounced 37% in the last month, although it is still struggling to make up recently lost ground. Looking further back, the 16% rise over the last twelve months isn't too bad notwithstanding the strength over the last 30 days.
Cytosorbents Corporation(納斯達克股票代碼:CTSO)的股東們無疑很高興地看到股價在上個月反彈了37%,儘管它仍在努力彌補最近的跌勢。再往前看,儘管在過去的30天中表現強勁,但過去十二個月的16%漲幅還不錯。
Even after such a large jump in price, Cytosorbents may still be sending buy signals at present with its price-to-sales (or "P/S") ratio of 2.3x, considering almost half of all companies in the Medical Equipment industry in the United States have P/S ratios greater than 3.4x and even P/S higher than 8x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
即使在價格大幅上漲之後,Cytosorbents目前仍可能以2.3倍的市盈率發出買入信號,因爲美國醫療設備行業幾乎有一半的公司的市盈率超過3.4倍,即使市盈率高於8倍也並非不尋常。儘管如此,我們需要更深入地挖掘以確定降低市盈率是否有合理的基礎。
Check out our latest analysis for Cytosorbents
查看我們對細胞吸附劑的最新分析
![](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20231229/0-6e941720a6af064adde5ba145c0d4b7f-0-a360f679ebc6608dd54d5c46913a82a0.png/big)
NasdaqCM:CTSO Price to Sales Ratio vs Industry December 28th 2023
納斯達克股票代碼:CTSO 與行業的股價銷售比率 2023 年 12 月 28 日
What Does Cytosorbents' Recent Performance Look Like?
細胞吸附劑的近期表現如何?
Recent times haven't been great for Cytosorbents as its revenue has been rising slower than most other companies. The P/S ratio is probably low because investors think this lacklustre revenue performance isn't going to get any better. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.
最近對Cytosorbents來說,情況並不理想,因爲其收入的增長速度比大多數其他公司都要慢。市盈率可能很低,因爲投資者認爲這種乏善可陳的收入表現不會好轉。如果你仍然喜歡這家公司,你希望收入不會惡化,也希望在股票失寵的時候買入一些股票。
Keen to find out how analysts think Cytosorbents' future stacks up against the industry? In that case, our free report is a great place to start.
想了解分析師如何看待細胞吸附劑的未來與該行業的對立嗎?在這種情況下,我們的免費報告是一個很好的起點。
Do Revenue Forecasts Match The Low P/S Ratio?
收入預測與低市盈率相匹配嗎?
The only time you'd be truly comfortable seeing a P/S as low as Cytosorbents' is when the company's growth is on track to lag the industry.
只有當公司的增長有望落後於行業時,你才能真正放心地看到像細胞吸附劑一樣低的市盈率。
If we review the last year of revenue growth, the company posted a worthy increase of 2.7%. However, due to its less than impressive performance prior to this period, revenue growth is practically non-existent over the last three years overall. Therefore, it's fair to say that revenue growth has been inconsistent recently for the company.
如果我們回顧一下去年的收入增長,該公司公佈了2.7%的可觀增長。但是,由於在此之前的表現並不令人印象深刻,在過去三年中,總體收入幾乎沒有增長。因此,可以公平地說,該公司最近的收入增長一直不穩定。
Looking ahead now, revenue is anticipated to climb by 28% each year during the coming three years according to the five analysts following the company. Meanwhile, the rest of the industry is forecast to only expand by 9.8% each year, which is noticeably less attractive.
現在展望未來,根據關注該公司的五位分析師的說法,預計未來三年收入將每年增長28%。同時,預計該行業的其他部門每年僅增長9.8%,這明顯降低了吸引力。
In light of this, it's peculiar that Cytosorbents' P/S sits below the majority of other companies. It looks like most investors are not convinced at all that the company can achieve future growth expectations.
有鑑於此,奇怪的是,Cytosorbents的市盈率低於大多數其他公司。看來大多數投資者根本不相信公司能夠實現未來的增長預期。
The Key Takeaway
關鍵要點
The latest share price surge wasn't enough to lift Cytosorbents' P/S close to the industry median. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.
最近的股價上漲不足以使Cytosorbents的市盈率接近行業中位數。儘管市銷比不應該成爲決定你是否買入股票的決定性因素,但它是衡量收入預期的有力晴雨表。
Cytosorbents' analyst forecasts revealed that its superior revenue outlook isn't contributing to its P/S anywhere near as much as we would have predicted. There could be some major risk factors that are placing downward pressure on the P/S ratio. While the possibility of the share price plunging seems unlikely due to the high growth forecasted for the company, the market does appear to have some hesitation.
Cytosorbents的分析師預測顯示,其優異的收入前景對其市盈率的貢獻沒有我們預期的那麼多。可能會有一些主要的風險因素給市盈率帶來下行壓力。儘管由於預計該公司將實現高增長,股價暴跌的可能性似乎不大,但市場似乎確實有些猶豫。
You should always think about risks. Case in point, we've spotted 3 warning signs for Cytosorbents you should be aware of.
你應該時刻考慮風險。舉個例子,我們發現了你應該注意的3種細胞吸附劑警告信號。
If you're unsure about the strength of Cytosorbents' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
如果您不確定Cytosorbents業務的實力,爲什麼不瀏覽我們的互動式股票清單,其中列出了一些您可能錯過的其他公司的業務基礎穩健的股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。